About this trial
People living in high TB burden communities who undergo active case finding for TB may have chest X-ray changes suggestive of TB but their sputum test can be negative for the TB bacteria or they are unable to provide a sputum sample. This means they have bacteriologically unconfirmed TB. These individuals often have minimal or no symptoms and face uncertainty in clinical management-either receiving full 24-weeks TB treatment or often being discharged without treatment, risking loss to follow-up.
The RADIO-TB trial aims to address the following main questions in relation to people with bacteriologically unconfirmed TB.
1. What is the risk of progression if treatment is not immediately started but there is close and careful follow-up over 78 weeks? 2. If treatment is started immediately what is the shortest duration of TB treatment that is as effective as the standard 24-week TB treatment? 3. Are there better tests to confirm TB than the current routinely used, sputum-based tests? 4. What is the cost effectiveness of different treatment strategies and what might the impact on transmission be within communities?
Participants in the trial will be randomized into six groups: five receiving immediate standard TB treatment of varying durations (8 to 24 weeks), and one receiving deferred treatment with close monitoring. Deferred treatment will be initiated only if clinical deterioration occurs or TB is later confirmed. Participants will be closely followed for 78 weeks with at least 11 clinic visits.
Eligibility criteria
Qualifiers
Aged ≥16 years old on day of randomisation
≥25kg in weight on day of randomisation
Participation in community or facility-based active case finding for TB by CXR
Digital CXR with Computer Aided Detection software score above threshold for sputum investigation for Mtb according to local guidance ≤21 days prior to randomisation
Disqualifiers
Sputum sample from active case finding or screening confirmed as positive for Mtb by WHO approved rapid molecular test for Mtb
Previous history of pulmonary TB
TB preventive therapy taken within the last 6 months
>1 dose of treatment with anti-tuberculous activity taken in the 21 days prior to randomisation
Trial design
Treatments tested in this trial
- Isoniazid (H)
- Rifampicin (R)
- Pyrazinamide (Z)
- Ethambutol (E)
Treatment groups
6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
University College, London
Lead sponsor
National University of Medical Sciences, Pakistan
Collaborator
Aurum Institute
Collaborator
Biomedical Research and Training Institute, Zimbabwe
Collaborator
Foundation for Innovative New Diagnostics, Switzerland
Collaborator
KTH Royal Institute of Technology
Collaborator
London School of Hygiene and Tropical Medicine
Collaborator
Wits Health Consortium (Pty) Ltd
Collaborator